Furthermore, we observed limited efficacy of cabozantinib in c-Myc-induced spontaneous tumor mouse models, indicating that high c-Myc expression constitutes a key factor contributing to cabozantinib resistance in hepatocellular carcinoma cells. This evidence concerns the gene MYC and hepatocellular carcinoma.